AKTX Akari Therapeutics Plc
$8.58▲ +12.45%
Healthcare
Other
Volume 38.5K
Avg Volume (10D) 37.9K
Key Metrics & Fundamentals
Market Cap
$19.61M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.02 - 33.60
% vs 50 MA
-7.22%
% vs 200 MA
-5.70%
RSI-14
48.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
2.08
Free Cash Flow
-$3.11M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.60M
COGS
–
Operating Exp
$4.60M
Operating Income
-$4.60M
EBIT
-$4.60M
Pretax Income
-$4.81M
Net Income
-$4.81M
EPS (Diluted)
0.00
Price & Volume History
Loading chart…
Recent News
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
GlobeNewswire · Oct 15, 2026 9:20 AM ET
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
GlobeNewswire · Oct 13, 2026 9:01 AM ET
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
GlobeNewswire · Oct 1, 2026 8:25 AM ET
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
GlobeNewswire · Sep 8, 2026 9:15 AM ET
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
GlobeNewswire · Aug 18, 2026 8:53 AM ET
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
GlobeNewswire · Aug 13, 2026 4:15 PM ET
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
GlobeNewswire · Aug 4, 2026 8:50 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AKTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.